hydroxyprogesterone caproate
Selected indexed studies
- 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis. (Obstet Gynecol, 2019) [PMID:30741815]
- Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis. (J Matern Fetal Neonatal Med, 2020) [PMID:30626240]
- 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? (Semin Perinatol, 2017) [PMID:28947068]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis. (2019) pubmed
- Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis. (2020) pubmed
- 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? (2017) pubmed
- Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis. (2019) pubmed
- 17 Alpha-hydroxyprogesterone caproate use in a rural state. (2022) pubmed
- Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth. (2021) pubmed
- Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice. (2013) pubmed
- Racial and ethnic representation in 17-hydroxyprogesterone caproate preterm birth prevention studies: a systematic review. (2022) pubmed
- What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. (2023) pubmed
- Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate. (2023) pubmed